
-
Serie A chief blasts Rabiot's criticism of Milan match in Australia
-
From refugee to Nobel: Yaghi hails science's 'equalising force'
-
De Minaur, Auger-Aliassime through to Shanghai quarter-finals
-
Canal Istanbul stirs fear and uncertainty in nearby villages
-
Root backs England to end Ashes drought in Australia
-
British PM Starmer hails India opportunities after trade deal
-
England captain Kane could miss Wales friendly
-
Tennis increases support for players under corruption, doping investigation
-
Russia says momentum from Putin-Trump meeting 'gone'
-
Gold tops $4,000 for first time as safe haven shines
-
EU wants key sectors to use made-in-Europe AI
-
De Minaur, Rinderknech through to Shanghai quarter-finals
-
Gisele Pelicot says 'never' gave consent to accused rapist
-
Thousands stranded as record floods submerge Vietnam streets
-
Sabalenka battles to keep Wuhan record alive, Pegula survives marathon
-
Trio wins chemistry Nobel for new form of molecular architecture
-
Tarnished image and cheating claims in Malaysia football scandal
-
Hamas says 'optimism prevails' in Gaza talks with Israel
-
Family affair as Rinderknech joins Vacherot in Shanghai quarters
-
New documentary shows life in Gaza for AFP journalists
-
Tennis stars suffer, wilt and quit in 'brutal' China heat
-
Wildlife flee as floods swamp Indian parks
-
Record flooding hits Vietnam city, eight killed in north
-
Battling cancer made Vendee Globe win 'more complicated', says skipper Dalin
-
England, Portugal, Norway closing in on 2026 World Cup
-
Child protection vs privacy: decision time for EU
-
Bear injures two in Japan supermarket, man killed in separate attack
-
In Simandou mountains, Guinea prepares to cash in on iron ore
-
Morikawa says not to blame for 'rude' Ryder Cup fans
-
Far right harvests votes as climate rules roil rural Spain
-
'Return to elegance': highlights from Paris Fashion Week
-
Britain's storied Conservative party faces uncertain future
-
New Zealand's seas warming faster than global average: report
-
Snakebite surge as Bangladesh hit by record rains
-
Yankees deny Blue Jays playoff sweep as Mariners beat Tigers
-
Australia police foil 'kill team' gang hit near daycare centre
-
US, Qatar, Turkey to join third day of Gaza peace talks in Egypt
-
Gold tops $4,000 for first time as traders pile into safe haven
-
Indian garment exporters reel under US tariffs
-
NBA back in China after six-year absence sparked by democracy tweet
-
Energy storage and new materials eyed for chemistry Nobel
-
Trump unlikely to win Nobel Peace Prize, but who will?
-
Qatar, Turkey to join third day of Gaza peace talks in Egypt
-
Study finds women have higher genetic risk of depression
-
Dolly Parton's sister calls for fan prayers over health issues
-
On Trump's orders, 200 troops from Texas arrive in Illinois
-
Two bodies found, two missing after Madrid building collapse
-
Panthers raise banner as NHL three-peat bid opens with win
-
KDC and NESR Secure Award for Integrated Well Delivery Campaign in Jordan
-
Medical Care Technologies (OTC PINK:MDCE) Initiates Preparatory Phase for Self-Conducted Research Studies on AI Mental Health and Preventive Biometrics Modules

Biorasi Unveils New Website to Drive Sponsor Success with Biotech-Centric Strategies and Modular CRO Solutions
Relaunch puts customized CRO services front and center for today's Biotech and Biopharma innovators.
AVENTURA, FL / ACCESS Newswire / October 8, 2025 / Biorasi, a leading global full-service contract research organization (CRO), has relaunched its website to reflect a bold new direction: Empowering biotech sponsors with modular clinical trial solutions, AI-powered tools, and a renewed focus on sponsor-centric strategy.
"The future of clinical research belongs to those who can adapt, innovate, and deliver," said Chris O'Brien, CEO of Biorasi. "Our new website reflects a strategic evolution - one that puts biotech sponsors at the center of smarter, faster, and more flexible trials. It's a touchstone for the modular solutions and AI-powered tools that will define the next era of clinical success."
Key updates to the website include:
Focused Study Solutions: Critical standalone service offerings deliver the same high-performance features found in Biorasi's full-service strategies:
Study Rescue and Recovery Packages: Designed to salvage struggling clinical trials and restore timelines.
Flexible Data Sciences Solutions: Advanced analytics and biostatistics available as standalone services.
Specialized Services: Including Quality Assurance, Clinical Monitoring, and Safety & Pharmacovigilance, tailored to sponsor needs.
Accelerated Startup Modules: Fast-track solutions for trials requiring rapid market entry.
AI-Powered Feasibility: Dynamic clinical site modeling combined with targeted feasibility outreach and enrollment forecasting.
New Sponsor Strategy: A sharpened focus on the CRO competencies that matter most: Reliability, Flexibility, and Accessibility.
The redesigned website celebrates Biorasi's over two decades of industry leadership, clinical trial experience, and operational excellence:
Over 200 global studies executed.
Five FDA approvals in the past seven years.
$150M+ in recovered rescue studies.
6 weeks or less for database go-live.
Kickoff Meetings in 10 business days after LOI/WO.
60% repeat business from returning sponsors.
Studies conducted in 48 countries, reaching 65% of the global population.
About Biorasi
Biorasi is a global clinical research organization (CRO) that delivers speed-to-market strategies for small to midsized biotech and biopharma sponsors. With over two decades of expertise in running clinical trials across dermatology, oncology, neurology, nephrology, and other key therapeutic areas, Biorasi leverages reliable, flexible, and accessible solutions necessary to succeed in today's dynamic and evolving clinical trials industry. Contact Biorasi at [email protected] / (786) 388-0700.
SOURCE: Biorasi, LLC
View the original press release on ACCESS Newswire
J.Williams--AMWN